Pharmacovigilance Considerations for Biosimilars in the USA
about
Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.The biosimilars journey: current status and ongoing challenges
P2860
Pharmacovigilance Considerations for Biosimilars in the USA
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacovigilance Considerations for Biosimilars in the USA
@ast
Pharmacovigilance Considerations for Biosimilars in the USA
@en
type
label
Pharmacovigilance Considerations for Biosimilars in the USA
@ast
Pharmacovigilance Considerations for Biosimilars in the USA
@en
prefLabel
Pharmacovigilance Considerations for Biosimilars in the USA
@ast
Pharmacovigilance Considerations for Biosimilars in the USA
@en
P2860
P1433
P1476
Pharmacovigilance Considerations for Biosimilars in the USA
@en
P2093
Gustavo Grampp
Thomas Felix
P2860
P2888
P304
P356
10.1007/S40259-015-0137-2
P577
2015-09-29T00:00:00Z